Predicts which treatments fit a patient's biomarkers and how confident that prediction is.
Consented intake · your records travel with you · nothing moves without your sign-off
MNM Bioscience works on biomarker-drug matching for cancer treatment. Based on the disease profile from a patient's test data, it recommends the options with the most likely effective response, predicts treatment response, and assesses confidence in the expected outcome. It is for patients who want their treatment shortlist built from the best available global thinking.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how MNM Bioscience handles billing.
We don't have confirmed insurance details for MNM Bioscience yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in MNM's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Identify the best treatment ideas using the best global thinking, predict best treatment response
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Matches your tumor's biomarkers to the therapies most likely to work for you — mapping your molecular profile to targeted and approved options.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.